cell and gene therapies

Patients

Cell and gene therapies and the tricky question of patient s...

Cell and gene therapies represent the cutting edge of pharma technology, but how are patients experiencing this treatment revolution?

Market Access

Collaboration is key to tackling geographical boundaries in ...

Unlike most biopharmaceuticals, it is often a struggle to manufacture cell and gene therapies (CGTs) in disparate geographies.

News

Merck builds in cell, gene therapies with Mirus Bio deal

Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a

Patients

Conference report: Reuters Pharma Europe

In this special edition of the pharmaphorum podcast, the tables have turned as Jonah Comstock puts edito

Market Access

How manufacturing keeps pace with innovation in cell and gen...

Cell and gene therapies are one of the most fast-moving and paradigm-shifting areas in pharmaceutical development today, bringing curative treatments to patients for the first time for cert

Market Access